Skip to main content
Top
Published in: Familial Cancer 3/2023

29-11-2022 | Endometrial Cancer | Brief Report

A PMS2 non-canonical splicing site variant leads to aberrant splicing in a patient suspected for lynch syndrome

Authors: Ahmed Bouras, Pierre Naibo, Clémentine Legrand, François Le Marc’hadour, Eric Ruano, Chloé Grand-Masson, Cedrick Lefol, Qing Wang

Published in: Familial Cancer | Issue 3/2023

Login to get access

Abstract

The PMS2 gene is one of the DNA mismatch repair genes (MMR) implicated in Lynch syndrome (LS). A subset of PMS2 pathogenic variants (PVs) are splice variants mostly affecting canonical GT/AG splicing sequences. However, the majority of the intronic variants outside canonical splice sites remained as variants of unknown significance, even though some of them would alter the splicing process. In this report, we describe the analysis of such an intronic variant (c.251-5T > C) detected in an 82-year-old patient diagnosed with endometrial cancer displaying microsatellite instability and the loss of PMS2 expression displayed. RNA analysis demonstrated that this variant lead to the complete exon 4 skipping, resulting in the synthesis of a truncated protein. This finding shows the relevance of functional RNA analysis in the non-canonical intronic variant assessment and the importance of systematic evaluation of MSI/loss of expression of MMR genes for LS screening in patients with endometrial cancers.
Literature
2.
go back to reference Aaltonen LA, Peltomäki P, Mecklin JP et al (1994) Replication errors in benign and malignant tumors from hereditary nonpolyposis colorectal cancer patients. Cancer Res 54:1645–1648PubMed Aaltonen LA, Peltomäki P, Mecklin JP et al (1994) Replication errors in benign and malignant tumors from hereditary nonpolyposis colorectal cancer patients. Cancer Res 54:1645–1648PubMed
Metadata
Title
A PMS2 non-canonical splicing site variant leads to aberrant splicing in a patient suspected for lynch syndrome
Authors
Ahmed Bouras
Pierre Naibo
Clémentine Legrand
François Le Marc’hadour
Eric Ruano
Chloé Grand-Masson
Cedrick Lefol
Qing Wang
Publication date
29-11-2022
Publisher
Springer Netherlands
Published in
Familial Cancer / Issue 3/2023
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-022-00323-y

Other articles of this Issue 3/2023

Familial Cancer 3/2023 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine